Eculizumab treatment in atypical hemolytic uremic syndrome: Correlation between functional complement tests and drug levels

M Cugno, V Capone, S Griffini, E Grovetti… - Journal of …, 2022 - Springer
… Thirteen patients were treated to prevent the disease in kidney graft. Patients with aHUS in
It can be argued that children may have different pharmacokinetics compared with adults. …

Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome

R Lo, S Alexander, J Moss, A Siddiqi… - The Journal of Allergy …, 2019 - jaci-inpractice.org
… For logistical reasons, intradermal testing was done 2 weeks later and was positive with
a … This case illustrates how rapid drug desensitization can help a young child continue first-line …

Atypical hemolytic uremic syndrome: a meta‐analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens

V Krishnappa, M Gupta, M Elrifai… - Therapeutic …, 2018 - Wiley Online Library
Eculizumab, a monoclonal antibody, binds to C5 to prevent … Reports of aHUS cases and
use of eculizumab significantly … to the precedent for unknown reasons. Although significant …

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective

M Ter Avest, RN Bouwmeester… - Nephrology dialysis …, 2023 - academic.oup.com
… For adult patients and children weighing ˃40 kg, eculizumab … of eculizumab treatment
dictate that one should aim to avoid … in this study for logistical reasons. Although one may argue …

Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab

AG Raufi, S Scott, O Darwish, K Harley, K Kahlon… - Hematology …, 2019 - mdpi.com
… to prevent premature apheresis removal of rituximab, which was added as a salvage agent
for lupus nephritis)10 with plan to convert to eculizumab … effects of eculizumab in a child with …

Atypical HemolyticUremic Syndrome: A Clinical Review

A Nayer, A Asif - American journal of therapeutics, 2016 - journals.lww.com
… to their illness during the acute phase, nearly half develop end-… Study 3 was a retrospective
analysis involving 19 children with … who discontinued eculizumab therapy for various reasons

Atypical hemolytic uremic syndrome in children aged< 2 years

N Çakar, ZB Ozcakar, F Ozaltin, M Koyun… - Nephron, 2018 - karger.com
… for various reasons, including … eculizumab following the onset of aHUS, it was discontinued
in 14 patients who were monitored closely during follow-up for the signs of recurrence. End-…

[HTML][HTML] Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature

N Thomson, M Ulrickson - Clinical Case Reports, 2016 - ncbi.nlm.nih.gov
… , thrombotic microangiopathy, and subsequent end‐organ damage 1. It is distinguished from
typical hemolytic uremic syndrome (HUS) in that it lacks coexisting disease such as Shiga‐…

Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence

U Mahat, RB Matar, SJ Rotz - Pediatric Blood & Cancer, 2019 - Wiley Online Library
… in the pathogenesis of atypical hemolytic uremic syndrome. … reasoning, and adaptive behavior
were comparable to their … 33 children from 15 centers in France treated with eculizumab

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

TJ Mauch, MR Chladek, S Cataland… - Journal of …, 2023 - becarispublishing.com
… people who were caring for a child with aHUS. Patients had … One of the main reasons they
preferred ravulizumab was that … This approach was taken to prevent unauthorized access to …